Literature DB >> 15084259

Integration of Smad and forkhead pathways in the control of neuroepithelial and glioblastoma cell proliferation.

Joan Seoane1, Hong-Van Le, Lijian Shen, Stewart A Anderson, Joan Massagué.   

Abstract

FoxO Forkhead transcription factors are shown here to act as signal transducers at the confluence of Smad, PI3K, and FoxG1 pathways. Smad proteins activated by TGF-beta form a complex with FoxO proteins to turn on the growth inhibitory gene p21Cip1. This process is negatively controlled by the PI3K pathway, a known inhibitor of FoxO localization in the nucleus, and by the telencephalic development factor FoxG1, which we show binds to FoxO-Smad complexes and blocks p21Cip1 expression. We suggest that the activity of this network confers resistance to TGF-beta-mediated cytostasis during the development of the telencephalic neuroepithelium and in glioblastoma brain tumor cells.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15084259     DOI: 10.1016/s0092-8674(04)00298-3

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  391 in total

Review 1.  EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer.

Authors:  A Singh; J Settleman
Journal:  Oncogene       Date:  2010-06-07       Impact factor: 9.867

2.  Forkhead factor FoxO1 is essential for placental morphogenesis in the developing embryo.

Authors:  Anwarul Ferdous; Jesse Morris; Mohammad Joynal Abedin; Shandon Collins; James A Richardson; Joseph A Hill
Journal:  Proc Natl Acad Sci U S A       Date:  2011-09-19       Impact factor: 11.205

3.  Myc-induced proliferation and transformation require Akt-mediated phosphorylation of FoxO proteins.

Authors:  Caroline Bouchard; Judith Marquardt; Alexandra Brás; René H Medema; Martin Eilers
Journal:  EMBO J       Date:  2004-07-08       Impact factor: 11.598

4.  NF-kappaB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression.

Authors:  Margit A Huber; Ninel Azoitei; Bernd Baumann; Stefan Grünert; Andreas Sommer; Hubert Pehamberger; Norbert Kraut; Hartmut Beug; Thomas Wirth
Journal:  J Clin Invest       Date:  2004-08       Impact factor: 14.808

5.  Proteasomal degradation of the FoxO1 transcriptional regulator in cells transformed by the P3k and Akt oncoproteins.

Authors:  Masahiro Aoki; Hao Jiang; Peter K Vogt
Journal:  Proc Natl Acad Sci U S A       Date:  2004-09-01       Impact factor: 11.205

6.  Distinct ontogenic and regional expressions of newly identified Cajal-Retzius cell-specific genes during neocorticogenesis.

Authors:  Hiroshi Yamazaki; Mariko Sekiguchi; Masako Takamatsu; Yasuto Tanabe; Shigetada Nakanishi
Journal:  Proc Natl Acad Sci U S A       Date:  2004-09-27       Impact factor: 11.205

Review 7.  Forkhead family transcription factor FoxO and neural differentiation.

Authors:  Qiang Wen; Haitao Wang; Peter J Little; Remi Quirion; Wenhua Zheng
Journal:  Neurogenetics       Date:  2012-03-28       Impact factor: 2.660

8.  Identification of the transcriptional targets of FOXP2, a gene linked to speech and language, in developing human brain.

Authors:  Elizabeth Spiteri; Genevieve Konopka; Giovanni Coppola; Jamee Bomar; Michael Oldham; Jing Ou; Sonja C Vernes; Simon E Fisher; Bing Ren; Daniel H Geschwind
Journal:  Am J Hum Genet       Date:  2007-10-31       Impact factor: 11.025

Review 9.  Modulation of oxidative stress as an anticancer strategy.

Authors:  Chiara Gorrini; Isaac S Harris; Tak W Mak
Journal:  Nat Rev Drug Discov       Date:  2013-12       Impact factor: 84.694

10.  The SWI/SNF ATPase Brm is a gatekeeper of proliferative control in prostate cancer.

Authors:  Hui Shen; Nathan Powers; Nitin Saini; Clay E S Comstock; Ankur Sharma; Katherine Weaver; Monica P Revelo; William Gerald; Erin Williams; Walter J Jessen; Bruce J Aronow; Gary Rosson; Bernard Weissman; Christian Muchardt; Moshe Yaniv; Karen E Knudsen
Journal:  Cancer Res       Date:  2008-12-15       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.